DACLATASVIR


DrugBank ID: db09102
DrugCentral: daclatasvir
Synonymous :bms-790052 | daclatasvir



Drug Sentece Context


Table 1. Analysis of context sentence of daclatasvir gene in 10 abstracts.

pmid sentence
32405423 Minimum estimated costs of production were US $0.93/day for remdesivir, $1.45/day for favipiravir, $0.08/day for hydroxychloroquine, $0.02/day for chloroquine, $0.10/day for azithromycin, $0.28/day for lopinavir/ritonavir, $0.39/day for sofosbuvir/daclatasvir and $1.09/day for pirfenidone.
32720571 Among 76 prescription antiviral drugs, four drugs (Raltegravir, Simeprevir, Cobicistat, and Daclatasvir) that are previously used for human immunodeficiency virus (HIV), hepatitis C virus (HCV), Ebola, and Marburg virus show higher binding energy and strong interaction with active sites of the receptor proteins.
32812025 We assessed the efficacy of sofosbuvir and daclatasvir with ribavirin for treating patients with COVID-19. […] Patients were randomly assigned to 400 mg sofosbuvir, 60 mg daclatasvir and 1200 mg ribavirin (intervention group) or to standard care (control group). […] The number of ICU admissions in the sofosbuvir/daclatasvir/ribavirin group was not significantly lower than the control group (0 versus 4, P = 0.109). […] The cumulative incidence of recovery was higher in the sofosbuvir/daclatasvir/ribavirin arm (Gray’s P = 0.033). […] There were trends in favour of the sofosbuvir/daclatasvir/ribavirin arm for recovery and lower death rates.
32812039 The aim of this trial was to assess if the addition of sofosbuvir and daclatasvir improved clinical outcomes in patients with moderate or severe COVID-19. […] Patients were randomized into a treatment arm receiving sofosbuvir and daclatasvir plus standard care, or a control arm receiving standard care alone. […] The addition of sofosbuvir and daclatasvir to standard care significantly reduced the duration of hospital stay compared with standard care alone.
32812051 Sofosbuvir and daclatasvir are direct-acting antivirals highly effective against hepatitis C virus. […] This trial evaluated the effectiveness of sofosbuvir in combination with daclatasvir in treating patients with COVID-19. […] Subjects were divided into two arms with one arm receiving ribavirin and the other receiving sofosbuvir/daclatasvir. […] Sixty-two subjects met the inclusion criteria, with 35 enrolled in the sofosbuvir/daclatasvir arm and 27 in the ribavirin arm. […] The median duration of stay was 5 days for the sofosbuvir/daclatasvir group and 9 days for the ribavirin group. […] The mortality in the sofosbuvir/daclatasvir group was 2/35 (6%) and 9/27 (33%) for the ribavirin group. […] The relative risk of death for patients treated with sofosbuvir/daclatasvir was 0.17 (95% CI 0.04-0.73, P = 0.02) and the number needed to treat for benefit was 3.6 (95% CI 2.1-12.1, P < 0.01).
32837113 A few promising leads with dual inhibition potential were identified among FDA approved antiviral drugs which include DB13879 (Glecaprevir), DB09102 (Daclatasvir), molecule DB09297 (Paritaprevir) and DB01072 (Atazanavir).
33024223 Other investigators have since demonstrated the ability of Sofosbuvir to inhibit SARS-CoV-2 replication in lung and brain cells; additionally, COVID-19 clinical trials with EPCLUSA and with Sofosbuvir plus Daclatasvir have been initiated in several countries.